In patients with metastatic castration-resistant prostate cancer (mCRPC), androgen deprivation therapy can have a detrimental effect on bone health. Joe O'Sullivan, MD, of Queen's University Belfast, Belfast, UK, brings this issue to light, highlighting the need to pay more attention to bone mineral loss in mCRPC patients receiving abiraterone therapy. Prof. O'Sullivan develops these conclusions after results from the ERA 223 trial (NCT02043678), which revealed an increased risk of bone fractures in mCRPC patients, regardless of radium-223 therapy. Speaking from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, Prof. O'Sullivan suggests the adminstration of bone health agents, such as zoledronic acid, in mCRPC patients receiving abiraterone.
- Radium-223 after abiraterone: symptomatic skeletal events in patients with mCRPC ( Download)
- Dr. Hwang on the Addition of Radium-223 to Abiraterone Acetate and Prednisone in mCRPC ( Download)
- Radium-223 in Advanced Disease ( Download)
- Treating mCRPC Patients With Radium 223 ( Download)
- Initiating Radium-223 Therapy in mCRPC ( Download)
- Dr. Kelly on Efficacy of Radium-223 Dichloride and Niraparib in Patients With mCRPC ( Download)
- Bone-Targeted Therapy for Prostate Cancer: Radium-223 ( Download)
- CLAYTON SMITH, MD PhD Radium-223 for Metastatic Prostate Cancer ( Download)
- Dr. Morris on Radium-223 Plus Docetaxel in Patients With Bone Metastasis From CRPC ( Download)
- Dr. Dreicer on Challenges of Radium-223 in Prostate Cancer ( Download)
- Reducing Skeletal-Related Events in Prostate Cancer ( Download)
- Should Radium 223 Be Given Earlier to Metastatic Prostate Cancer Patients ( Download)
- Choosing a Companion Drug to Radium-223 ( Download)
- ERA 223 and Implications for Clinical Practice ( Download)
- Dr. McKay on the Real-World Utilization of Radium-223 in mCRPC ( Download)
